Weight loss-associated induction of peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-γ correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice

Circulation

Volumn 110, Issue 20, 2004, Pages 3259-3269

  Verreth, Wim ^a   De Keyzer, Dieuwke ^a   Pelat, Michel ^b   Verhamme, Peter ^a   Ganame, Javier ^a   Bielicki, John K ^c   Mertens, Ann ^a   Quarck, Rozenn ^a   Benhabilès, Nora ^e   Marguerie, Gérard ^e   Mackness, Bharti ^d   Mackness, Mike ^d   Ninio, Ewa ^f   Herregods, Marie Christine ^a   Balligand, Jean Luc ^b   Holvoet, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e Clinigenetics   (France)

^f INSERM   (France)

Author keywords

Atherosclerosis; Circadian rhythm; Genes; Lipoproteins; Obesity

Indexed keywords

LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC OBESITY; DIET RESTRICTION; DIET THERAPY; DOWN REGULATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; GLUCOSE TRANSPORT; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR UPREGULATION; TRANSCRIPTION INITIATION; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; AORTA, THORACIC; ARTERIOSCLEROSIS; AUTOANTIBODIES; CIRCADIAN RHYTHM; ECHOCARDIOGRAPHY; GENE EXPRESSION REGULATION; GENOTYPE; GLUCOSE; HEART FUNCTION TESTS; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LEPTIN; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; MYOCARDIUM; OBESITY; OXIDATIVE STRESS; PPAR ALPHA; PPAR GAMMA; RECEPTORS, LDL; TRANSCRIPTION, GENETIC; UP-REGULATION; WEIGHT LOSS;

EID: 20844439184     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000147614.85888.7A     Document Type: Article

References (56)

1. Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975-980.
2. Abate N, Garg A, Peshock RM, et al. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 1995;96:88-98.
3. McLaughlin T, Abbasi F, Kim HS, et al. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women. Metabolism. 2001;50:795-800.
4. Henkin L, Bergman RN, Bowden DW, et al. Genetic epidemiology of insulin resistance and visceral adiposity: the IRAS Family Study design and methods. Ann Epidemiol. 2003;13:211-217.
5. Mertens A, Verhamme P, Bielicki JK, et al. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation. 2003;107:1640-1646.
6. Hasty AH, Shimano H, Osuga J, et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem. 2001;276:37402-37408.
7. Nagy TR, Clair AL. Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes Res. 2000;8:392-398.
8. Van Eck M, Twisk J, Hoekstra M, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem. 2003;278:23699-23705.
9. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002;30:e15.
10. Hedrick CC, Castellani LW, Warden CH, et al. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem. 1993;268:20676-20682.
11. Vercaemst R, Rosseneu M, Van Biervliet JP. Separation and quantitation of plasma lipoproteins by high-performance liquid chromatography. J Chromatogr. 1983;276:174-181.
12. Ludwig DS, Tritos NA, Mastaitis JW, et al. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest. 2001;107:379-386.
13. Bielicki JK, Forte TM. Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity. J Lipid Res. 1999;40:948-954.
14. Blankenberg S, Stengel D, Rupprecht HJ, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res. 2003;44:1381-1386.
15. Mackness MI, Arrol S, Abbott C, et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
16. Butz GM, Davisson RL. Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol Genomics. 2001;5:89-97.
17. Just A, Faulhaber J, Ehmke H. Autonomic cardiovascular control in conscious mice. Am J Physiol. 2000;279:R2214-R2221.
18. -/- mice in vivo. Circulation. 2003;107:2480-2486.
19. Stauss HM, Godecke A, Mrowka R, et al. Enhanced blood pressure variability in eNOS knockout mice. Hypertension. 1999;33:1359-1363.
20. Yang XP, Liu YH, Rhaleb NE, et al. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol. 1999;277:H1967-H1974.
21. Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem. 2001;276:41245-41254.
22. Komers R, Vrana A. Thiazolidinediones: tools for the research of metabolic syndrome X. Physiol Res. 1998;47:215-225.
23. Young PW, Cawthorne MA, Coyle PJ, et al. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes: association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes. 1995;44:1087-1092.
24. Hensley LL, Ranganathan G, Wagner EM, et al. Transgenic mice expressing lipoprotein lipase in adipose tissue: absence of the proximal 3′-untranslated region causes translational upregulation. J Biol Chem. 2003;278:32702-32709.
25. Hong G, Davis B, Khatoon N, et al. PPAR gamma-dependent antiinflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation. Biochem Biophys Res Commun. 2003;303:782-787.
26. Jansson PA, Pellme F, Hammarstedt A, et al. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J. 2003;17: 1434-1440.
27. Prusty D, Park BH, Davis KE, et al. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes. J Biol Chem. 2002;277: 46226-46232.
28. Klemm DJ, Leitner JW, Watson P, et al. Insulin-induced adipocyte differentiation: activation of CREB rescues adipogenesis from the arrest caused by inhibition of prenylation. J Biol Chem. 2001;276:28430-28435.
29. Tschritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003;52:239-243.
30. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:717-726.
31. Mead JR, Ramji DP. The pivotal role of lipoprotein lipase in atherosclerosis. Cardiovasc Res. 2002;55:261-269.
32. Takahashi S, Sakai J, Fujino T, et al. The very low density lipoprotein (VLDL) receptor: a peripheral lipoprotein receptor for remnant lipoproteins into fatty acid active tissues. Mol Cell Biochem. 2003;248: 121-127.
33. Ziouzenkova O, Perrey S, Asatryan L, et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A. 2003;100: 2730-2735.
34. Kim H, Haluzik M, Asghar Z, et al. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes. 2003;52:1770-1778.
35. Mulder H, Sorhede-Winzell M, Contreras JA, et al. Hormone-sensitive lipase null mice exhibit signs of impaired insulin sensitivity whereas insulin secretion is intact. J Biol Chem. 2003;278:36380-36388.
36. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 2001;15:2073-2084.
37. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21:844-848.
38. Holvoet P, Harris TB, Tracy RP, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition Study. Arterioscler Thromb Vasc Biol. 2003;23:1444-1448.
39. Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775-2779.
40. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481-488.
41. 't Hoen PA, Van der Lans CA, Van Eck M, et al. Aorta of apoE-deficient mice responds to atherogenic stimuli by a prelesional increase and subsequent decrease in the expression of antioxidant enzymes. Circ Res. 2003;93:262-269.
42. Nassar T, Sachais BS, Akkawi S, et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem. 2003;278:6187-6193.
43. Liang CP, Han S, Okamoto H, et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest. 2004;113: 764-773.
44. Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004;53:1068-1073.
45. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
46. Rajala MW, Scherer PE. Minireview: the adipocyte: at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144:3765-3773.
47. Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol. 2003;92:3J-9J.
48. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol. 2003;92:34J-41J.
49. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation. 2000;101:235-238.
50. Ikeda Y, Sugawara A, Taniyama Y, et al. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2. J Biol Chem. 2000;275:33142-33150.
51. Lee M, Sommerhoff CP, von Eckardstein A, et al. Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:2086-2091.
52. Makino M, Hayashi H, Takezawa H, et al. Circadian rhythms of cardiovascular functions are modulated by the baroreflex and the autonomic nervous system in the rat. Circulation. 1997;96:1667-1674.
53. Stauss HM, Persson PB. Role of nitric oxide in buffering short-term blood pressure fluctuations. News Physiol Sci. 2000;15:229-233.
54. Sega R, Corrao G, Bombelli M, et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension. 2002;39:710-714.
55. Ailhaud G. Cross talk between adipocytes and their precursors: relationships with adipose tissue development and blood pressure. Ann N Y Acad Sci. 1999;892:127-133.
56. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003;35:807-825.